GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Ludwig Enterprises Inc (OTCPK:LUDG) » Definitions » Buyback Yield %

Ludwig Enterprises (Ludwig Enterprises) Buyback Yield % : 0.00 (As of Jun. 04, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Ludwig Enterprises Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Ludwig Enterprises's current buyback yield was 0.00%.


Ludwig Enterprises Buyback Yield % Historical Data

The historical data trend for Ludwig Enterprises's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ludwig Enterprises Buyback Yield % Chart

Ludwig Enterprises Annual Data
Trend Dec22 Dec23
Buyback Yield %
- -

Ludwig Enterprises Quarterly Data
Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Buyback Yield % Get a 7-Day Free Trial - - - - -

Competitive Comparison of Ludwig Enterprises's Buyback Yield %

For the Medical Devices subindustry, Ludwig Enterprises's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ludwig Enterprises's Buyback Yield % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Ludwig Enterprises's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Ludwig Enterprises's Buyback Yield % falls into.



Ludwig Enterprises Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Ludwig Enterprises's Buyback Yield for the fiscal year that ended in Dec. 2023 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0) / 21.0655075
=0.00%

Ludwig Enterprises's annualized Buyback Yield for the quarter that ended in Mar. 2024 is calculated as

Buyback Yield=Net Issuance of Stock(Annualized) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) * Annualized Factor / Market Cap
=- (0 + 0) * 4 / 38.86625
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Mar. 2024) data.


Ludwig Enterprises Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Ludwig Enterprises's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ludwig Enterprises (Ludwig Enterprises) Business Description

Traded in Other Exchanges
N/A
Address
1749 VICTORIAN AVENUE, Suite C-350, Sparks, NV, USA, 89431
Ludwig Enterprises Inc is a publicly traded Medical Technology Holding Company with Precision Genomics, Inc. and MyRNA for Life, Inc. as wholly owned subsidiaries. The company's advancements in medical technology and Artificial Intelligence (AI) have awarded it with cutting-edge genomic tools. These genomic tools have the potential to detect diseases early but also to customize treatments that may improve patient outcomes and, in some cases, even extend life. Ludwig is at the forefront of this new era with their proprietary mRNA genetic technology that has the potential to detect genetic biomarkers for inflammatory-driven diseases, including but not limited to heart disease, diabetes, preeclampsia, and cancer. It manages its business on the basis of one operating and reportable segment.